Riliprubart

• CAT Number: I040379
• CAS Number: 2756228-76-7
• Purity: ≥95%

Riliprubart(CAT: I040379) (also known as SAR445088 or BIVV020) is a humanized IgG4 monoclonal antibody that selectively inhibits the activated form of C1s, a critical protease in the classical complement pathway. By blocking C1s activity, it prevents downstream complement activation while preserving the lectin and alternative pathways. Riliprubart is being developed for chronic inflammatory demyelinating polyneuropathy (CIDP) and other complement-mediated disorders. Clinical studies have demonstrated its potential for rapid disease control, reduced inflammation, and favorable tolerability. Supplied at high purity, Riliprubart is ideal for research in neuroimmunology, autoimmunity, and complement-targeted therapeutic development.